Vnitr Lek 2022, 68(3):178-180 | DOI: 10.36290/vnl.2022.035

Beta‑blockers after myocardial infarction and chronic coronary heart disease

Jiří Vítovec, Jindřich Špinar, Lenka Špinarová

I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně

Treatment with beta-blockers has been an essential part of secondary prevention after myocardial infarction or chronic CHD for several decades. Studies that have shown a beneficial prognostically beneficial effect of beta-blockers were conducted in the period prior to the routine use of reperfusion therapy. In patients who have been treated with fibrinolytic therapy, their contribution is less pronounced. The situation is even less clear in patients who are treated with primary percutaneous coronary intervention, as prospective studies and observational data from registries do not yet give a clear view of the indications and clinical contribution of beta-blockers, especially in the group with normal ejection fraction, without signs of heart failure. Here are the latest different studies from the South Korean and Danish national registries in patients with CHD without heart failure and the effect of beta-blockers on the long-term prognosis.

Keywords: betablockers, coronary heart disease, myocardial infarction, secondary prevention.

Published: April 26, 2022  Show citation